Table Filtering
Other Information
Release Statistics Download
GlyCosmos Glycolipids

Glycolipid entries from the LIPID MAPS Structure Database (LMSD).

Source Last Updated
LIPID MAPS Proteome Database (LMSD) June 16, 2024
Displaying entries 476 - 500 of 2342 in total
Sub Class LM ID Name LipidBank ID KEGG ID PubChem CID ChEBI ID Exact Mass Formula ▼
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505CG08
  • ClcNAc-Lex-5(d18:1/26:1(17Z))
  • GlcNAcbeta1-3Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z))
44261443 1714.028077 C84H151N3O32
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505CU08
  • GalNAcalpha1-3(Fucalpha1-2)Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z))
  • type II A antigen(d18:1/26:1(17Z))
44261547 1714.028077 C84H151N3O32
Galalpha1-3Galbeta1-4Glc- (Isoglobo series) LMSP0506BI08
  • Fucalpha1-3GlcNAcbeta1-3Galalpha1-3(GalNAcbeta1-4)Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z))
44261699 1714.028077 C84H151N3O32
Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AT02
  • Branched Forssman(d18:1/18:0)
  • GalNAcalpha1-3GalNAcbeta1-3(Galbeta1-3GalNAcbeta1-4)Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/18:0)
44260317 1822.992816 C84H150N4O38
Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc- (Lacto series) LMSP0504AO02
  • GalNAcalpha1-3Galbeta1-3GlcNAcbeta1-3Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/18:0)
44260725 1822.992816 C84H150N4O38
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505AN02
  • Galbeta1-4GlcNAcbeta1-3(GlcNAcbeta1-6)Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/18:0)
44261077 1822.992816 C84H150N4O38
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505BF02
  • GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/18:0)
44261221 1822.992816 C84H150N4O38
Galalpha1-3Galbeta1-4Glc- (Isoglobo series) LMSP0506AI02
  • GalNAcalpha1-3GalNAcbeta1-3Galalpha1-3(Galbeta1-4GlcNAcbeta1-6)Galbeta1-4Glcbeta-Cer(d18:1/18:0)
44261877 1822.992816 C84H150N4O38
Galalpha1-3Galbeta1-4Glc- (Isoglobo series) LMSP0506AJ02
  • GalNAcbeta1-3Galalpha1-3(GalNAcbeta1-4Galbeta1-4GlcNAcbeta1-6)Galbeta1-4Glcbeta-Cer(d18:1/18:0)
44261885 1822.992816 C84H150N4O38
Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502BB07
  • GalNAcalpha1-3GalNAcbeta1-3(GalNAcbeta1-4)Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))
44260386 1743.018241 C84H150N4O33
Galalpha1-3Galbeta1-4Glc- (Isoglobo series) LMSP0506AL07
  • GalNAcalpha1-3GalNAcbeta1-3Galalpha1-3(GlcNAcbeta1-6)Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))
44261906 1743.018241 C84H150N4O33
Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AX01
  • GalNAcbeta1-3Galalpha1-3Galalpha1-3Galalpha1-3Galalpha1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/16:0)
44260348 1874.961243 C84H150N2O43
Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AQ06
  • GalNAcbeta1-3Galalpha1-3Galalpha1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/26:0)
44260297 1691.012093 C82H150N2O33
Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502BF06
  • Galalpha1-3Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/26:0)
44260417 1691.012093 C82H150N2O33
Galalpha1-3Galbeta1-4Glc- (Isoglobo series) LMSP0506BA06
  • Galalpha1-3Galbeta1-3GalNAcbeta1-3Galalpha1-3Galbeta1-4Glcbeta-Cer(d18:1/26:0)
44261633 1691.012093 C82H150N2O33
Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AI06
  • Fucalpha1-2Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/26:0)
  • type IV H(d18:1/26:0)
44260233 1675.017178 C82H150N2O32
Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502BM06
  • Fucalpha2-3Galbeta1-3GalNAcbeta1-4Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/26:0)
44260473 1675.017178 C82H150N2O32
GalNAcbeta1-4Galbeta1-4Glc- (Ganglio series) LMSP0503AK06
  • Galalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-4Galbeta1-4Glcbeta-Cer(d18:1/26:0)
44260569 1675.017178 C82H150N2O32
Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc- (Lacto series) LMSP0504AE06
  • Galalpha1-3(Fucalpha1-2)Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/26:0)
  • type I B antigen(d18:1/26:0)
44260649 1675.017178 C82H150N2O32
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505AE06
  • Galalpha1-3(Fucalpha1-2)Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/26:0)
  • type II B antigen(d18:1/26:0)
44261009 1675.017178 C82H150N2O32
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505CV06
  • Gala 1-3Lex(d18:1/26:0)
  • Galalpha1-3Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/26:0)
44261553 1675.017178 C82H150N2O32
Galalpha1-3Galbeta1-4Glc- (Isoglobo series) LMSP0506AW06
  • Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galalpha1-3Galbeta1-4Glcbeta-Cer(d18:1/26:0)
44261617 1675.017178 C82H150N2O32
Galalpha1-3Galbeta1-4Glc- (Isoglobo series) LMSP0506BB06
  • Fucalpha1-2Galbeta1-3GalNAcbeta1-3Galalpha1-3Galbeta1-4Glcbeta-Cer(d18:1/26:0)
44261641 1675.017178 C82H150N2O32
Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc- (Lacto series) LMSP0504AI06
  • Fucalpha1-2Galbeta1-3(Fucalpha1-4)GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/26:0)
  • Leb(d18:1/26:0)
44260681 1659.022263 C82H150N2O31
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505AG06
  • Fucalpha1-2Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/26:0)
  • Ley-6(d18:1/26:0)
44261025 1659.022263 C82H150N2O31

About Release Notes Help Feedback

Click here to visit the beta site.


International Collaboration

GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.

Acknowledgements

Supported by JST NBDC Grant Number JPMJND2204

Partly supported by NIH Common Fund Grant #1U01GM125267-01


Logo License Policies Site Map

Contact: support@glycosmos.org

This work is licensed under Creative Commons Attribution 4.0 International


GlyCosmos Portal v4.1.0

Last updated: December 9, 2024